Literature DB >> 15715924

Historic perspectives and recent advances in major animal models of hypertension.

Zhong-jie Sun1, Zhong-e Zhang.   

Abstract

Hypertension and related cardiovascular diseases are the leading causes of death in many countries. The etiology of human essential hypertension is largely unknown. It is highly likely that hypertension is a complex and multifactorial disease resulting from the interaction of multiple genetic and environmental factors. Animal models of hypertension have been proved to be useful to study the pathogenesis of, and to find a new therapy for, hypertension. The aim of this article is to briefly review the most widely used rodent models of experimental hypertension, including history and recent advances. These models are classified as genetically-induced, environmentally-induced, pharmacologically-induced, and renal-induced hypertension according to the way of induction; the typical representatives of each of these major types of experimental hypertension are spontaneous hypertension, cold-induced hypertension, DOCA-salt-induced hypertension, and renal-induced hypertension, respectively. The processes of induction of hypertension, possible pathogenesis, characteristics, advantages, and limitations of these animal models are reviewed. In addition, the clinical implications of the above experimental models of hypertension are addressed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15715924     DOI: 10.1111/j.1745-7254.2005.00054.x

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  12 in total

1.  Klotho gene delivery prevents the progression of spontaneous hypertension and renal damage.

Authors:  Yuhong Wang; Zhongjie Sun
Journal:  Hypertension       Date:  2009-07-27       Impact factor: 10.190

Review 2.  Rodent models of heart failure: an updated review.

Authors:  A C Gomes; I Falcão-Pires; A L Pires; C Brás-Silva; A F Leite-Moreira
Journal:  Heart Fail Rev       Date:  2013-03       Impact factor: 4.214

Review 3.  Can we predict the blood pressure response to renal denervation?

Authors:  Gregory D Fink; Jeremiah T Phelps
Journal:  Auton Neurosci       Date:  2016-07-30       Impact factor: 3.145

4.  Inhibition of phosphodiesterase-1 attenuates cold-induced pulmonary hypertension.

Authors:  Patrick Crosswhite; Zhongjie Sun
Journal:  Hypertension       Date:  2013-01-14       Impact factor: 10.190

5.  The Role of Plasma Triglyceride/High-Density Lipoprotein Cholesterol Ratio to Predict New Cardiovascular Events in Essential Hypertensive Patients.

Authors:  Osman Turak; Barış Afşar; Fırat Ozcan; Fatih Öksüz; Mehmet Ali Mendi; Çagrı Yayla; Adrian Covic; Nathan Bertelsen; Mehmet Kanbay
Journal:  J Clin Hypertens (Greenwich)       Date:  2015-12-22       Impact factor: 3.738

Review 6.  Animal Models in Cardiovascular Research: Hypertension and Atherosclerosis.

Authors:  Xin-Fang Leong; Chun-Yi Ng; Kamsiah Jaarin
Journal:  Biomed Res Int       Date:  2015-05-03       Impact factor: 3.411

7.  Repetitive Electroacupuncture Attenuates Cold-Induced Hypertension through Enkephalin in the Rostral Ventral Lateral Medulla.

Authors:  Min Li; Stephanie C Tjen-A-Looi; Zhi-Ling Guo; John C Longhurst
Journal:  Sci Rep       Date:  2016-10-24       Impact factor: 4.379

8.  Interaction effects of ultrafine carbon black with iron and nickel on heart rate variability in spontaneously hypertensive rats.

Authors:  Chuen-Chau Chang; Jing-Shiang Hwang; Chang-Chuan Chan; Tsun-Jen Cheng
Journal:  Environ Health Perspect       Date:  2007-07       Impact factor: 9.031

Review 9.  Aminopeptidases in Cardiovascular and Renal Function. Role as Predictive Renal Injury Biomarkers.

Authors:  Félix Vargas; Rosemary Wangesteen; Isabel Rodríguez-Gómez; Joaquín García-Estañ
Journal:  Int J Mol Sci       Date:  2020-08-05       Impact factor: 5.923

10.  Network Pharmacology Prediction and Pharmacological Verification Mechanism of Yeju Jiangya Decoction on Hypertension.

Authors:  Ting Wang; Mao He; Yuzhong Du; Suhong Chen; Guiyuan Lv
Journal:  Evid Based Complement Alternat Med       Date:  2021-05-10       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.